EDITORIAL

TRPV1 and cough

TRPV1 and cough

G P Anderson

Correspondence to:
Correspondence to:
Associate Professor G P Anderson PhD
Lung Disease Research Laboratories, Research Director, CRC for Chronic Inflammatory Diseases, Departments of Pharmacology and Medicine, University of Melbourne, Parkville, VIC 3010, Australia; gpa@unimelb.edu.au

---

Iodo-resiniferatoxin, a new TRPV1 inhibitor, shows promising antitussive activity in an animal model

---

Abbreviations: TRPV1, transient receptor potential vanilloid-1

Keywords: cough; transient receptor potential vanilloid-1 (TRPV1); iodo-resiniferatoxin

The first 150 words of the full text of this article appear below.

Cough is one of the most common respiratory complaints and intractable cough remains one of the most distressing and difficult to treat conditions of the lung. It is ironical that the billions of dollars spent worldwide on proprietary over the counter remedies of questionable efficacy¹ for cough exceeds, by orders of magnitude, the money spent on basic cough research. It is therefore not surprising that the cough pharmacopoeia has altered little in the last 50 years, with no important advances over opiate based compounds and cromones. However, basic researchers have not been idle. In this issue of Thorax Trevisani and colleagues² present new information pointing to a causative role for an ion channel called transient receptor potential vanilloid-1 (TRPV1) in cough. They show that the highly selective and potent TRPV1 inhibitor iodo-resiniferatoxin, derived from a plant toxin found in Euphorbia species, strongly suppresses cough induced by inhaled . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?